AbbVie (ABBV) Is Today's Pre-Market Laggard Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Trade-Ideas LLC identified
(
) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified AbbVie as such a stock due to the following factors:
- ABBV has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $523.0 million.
- ABBV traded 423,303 shares today in the pre-market hours as of 7:33 AM.
- ABBV is down 5.4% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABBV with the Ticky from Trade-Ideas. See the FREE profile for ABBV NOW at Trade-Ideas
More details on ABBV:
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The stock currently has a dividend yield of 3.4%. ABBV has a PE ratio of 55.0. Currently there are 8 analysts that rate AbbVie a buy, no analysts rate it a sell, and 4 rate it a hold.
The average volume for AbbVie has been 9.8 million shares per day over the past 30 days. AbbVie has a market cap of $96.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.66 and a short float of 0.9% with 1.55 days to cover. Shares are down 8.9% year-to-date as of the close of trading on Tuesday.
Analysis:
rates AbbVie as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 13.1%. Since the same quarter one year prior, revenues slightly increased by 6.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Pharmaceuticals industry and the overall market, ABBVIE INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
- The gross profit margin for ABBVIE INC is currently very high, coming in at 83.16%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -14.85% is in-line with the industry average.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 171.8% when compared to the same quarter one year ago, falling from $1,128.00 million to -$810.00 million.
- Net operating cash flow has significantly decreased to -$578.00 million or 146.42% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- You can view the full AbbVie Ratings Report.
null